Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer

BACKGROUND: Pancreatic cancer is a rapidly fatal disease with gemcitabine remaining the first-line therapy. We performed a genotype–phenotype association study to identify biomarkers for predicting gemcitabine treatment outcome. MATERIALS AND METHODS: We selected the top 200 single nucleotide polymo...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Liang, Zhang, Jian-Wei, Jenkins, Gregory, Xie, Fang, Carlson, Erin E., Fridley, Brooke L., Bamlet, William R., Petersen, Gloria M., McWilliams, Robert R., Wang, Liewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083195/
https://www.ncbi.nlm.nih.gov/pubmed/27749787
http://dx.doi.org/10.1097/FPC.0000000000000241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083195/
https://www.ncbi.nlm.nih.gov/pubmed/27749787
http://dx.doi.org/10.1097/FPC.0000000000000241

Ejemplares similares